Followers | 14 |
Posts | 1963 |
Boards Moderated | 0 |
Alias Born | 04/16/2024 |

Monday, January 20, 2025 4:56:10 PM
cliffnotes. Keep in mind the company is based in Jerusalem.
- The transaction represents an implied pro forma equity value of approximately $1 billion and is expected to provide up to $367 million in gross proceeds, including up to $275 million of cash held in the trust account of Healthcare Capital Corp. (Nasdaq: HCCC) and a $92 million PIPE.
- Citigroup is acting as financial advisor to Alpha Tau. Citigroup, Piper Sandler, and Cantor Fitzgerald are acting as joint placement agents on the PIPE. Cantor Fitzgerald is acting as a capital markets advisor to HCC. Value Base M&A Ltd. is also acting as financial advisor on the transaction.
Latham & Watkins LLP and Meitar | Law Offices are acting as legal advisors to Alpha Tau. Ellenoff Grossman & Schole LLP and FBC & Co. are acting as legal advisors to HCC. Winston & Strawn LLP is acting as legal advisor to the placement agents.
Recent DRTS News
- Alpha Tau Announces Full Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/12/2025 08:02:00 PM
- Alpha Tau to Participate in March Investor Conferences • GlobeNewswire Inc. • 02/27/2025 02:00:00 PM
- Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification • GlobeNewswire Inc. • 02/24/2025 01:30:00 PM
- Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease • GlobeNewswire Inc. • 02/03/2025 01:30:00 PM
- Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day • GlobeNewswire Inc. • 01/27/2025 02:00:00 PM
- Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day • GlobeNewswire Inc. • 12/18/2024 01:30:00 PM
- Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor • GlobeNewswire Inc. • 12/17/2024 02:00:00 PM
- Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/11/2024 01:30:00 PM
- Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium • GlobeNewswire Inc. • 12/06/2024 01:30:00 PM
- Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/19/2024 09:00:00 PM
- Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference • GlobeNewswire Inc. • 11/13/2024 01:30:00 PM
- Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme • GlobeNewswire Inc. • 10/21/2024 12:30:24 PM
- Alpha Tau Treats First Patient with Recurrent Lung Cancer • GlobeNewswire Inc. • 10/10/2024 12:30:00 PM
- Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC • GlobeNewswire Inc. • 09/20/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/22/2024 12:32:25 PM
- Alpha Tau to Participate in the H.C. Wainwright 26th Annual Global Investment Conference, the Sidoti Small-Cap Virtual Investor Conference, the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference, and the Lytham Partners Fall 2024 Investor Con • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 08:10:17 PM
- Alpha Tau Medical Announces Second Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/14/2024 08:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/14/2024 08:01:44 PM
- Alpha Tau Announces Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
- Alpha Tau to Present at the Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/21/2024 12:45:00 PM
- Alpha Tau Medical Announces First Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/20/2024 08:01:00 PM
- Alpha Tau Announces Alpha DaRT Treatment of First Patient with Liver Metastases of Colorectal Cancer • GlobeNewswire Inc. • 05/13/2024 12:30:00 PM
- Alpha Tau Presents Preclinical Data Demonstrating Abscopal Immune Effect in Pancreatic Murine Tumor Models at ESTRO 2024 Congress in Glasgow • GlobeNewswire Inc. • 05/06/2024 12:30:00 PM
- Alpha Tau to Participate in May Investor Conferences • GlobeNewswire Inc. • 05/01/2024 12:30:00 PM
UAV Corp. to Present Critical Inflation Test in 30 Days, Paving the Way to Secure Over $525 Million in DART Series Sales Contracts • UMAV • Mar 14, 2025 1:00 PM
Fifty 1 Labs, Inc. Completes Name and Symbol Change, Advances Toward Regaining 15c211 Compliance • FITY • Mar 14, 2025 10:30 AM
WIN-LIGHT GLOBAL FILES SEC SCHEDULE 13G DISCLOSING 1.96M SHARES OF PASSIVE INSTITUTIONAL INVESTOR OWNERSHIP • CNTM • Mar 14, 2025 7:13 AM
The Crypto Company Expands Leadership Team With Experienced Financial and Blockchain Professionals • CRCW • Mar 13, 2025 9:23 AM
ConnectM Announces $10 Million Share Repurchase Program • CNTM • Mar 13, 2025 9:13 AM
Sigyn CEO Note: An Emerging New Industry, 15 Years in the Making • SIGY • Mar 12, 2025 9:41 AM